Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus FERROUS CITRATE FE 59.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus FERROUS CITRATE FE 59.
CIS-MDP vs FERROUS CITRATE FE 59
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Ferrous citrate Fe 59 is a radioactive isotope of iron used for diagnostic purposes. It is incorporated into hemoglobin in red blood cells, allowing visualization of erythropoiesis and imaging of the reticuloendothelial system.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
Ferrous citrate Fe 59 is a radioactive diagnostic tracer, not a therapeutic iron supplement. Typical adult dose: 2-10 µCi (0.074-0.37 MBq) intravenously as a single dose for iron absorption or red cell utilization studies.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life of Fe-59 from plasma is approximately 1.5-2 hours for free iron, but for total body iron, it is about 5-6 hours initially, followed by a slow phase of 6-10 days due to redistribution to storage sites. Clinically, the long half-life allows imaging of erythropoiesis over days.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Fe-59 is primarily excreted via feces (80-90%) as unabsorbed iron, with minor renal excretion (<5%) and negligible biliary elimination. Absorbed iron is incorporated into hemoglobin and red blood cells, with loss via desquamation (~1 mg/day) not reflected in excretion fractions.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical